| abstract |
The present disclosure belongs to the technical field of medicine, and relates to dual receptor agonists of GIP and GLP-1, pharmaceutical compositions and uses. In particular, the present disclosure relates to compounds of formula I, pharmaceutical compositions comprising the same, and their use in the field of medicine as dual receptor agonists of GIP and GLP-1. The compound shown in formula I in the present disclosure exhibits excellent GIPR and GLP-1R agonistic activities and drug activities for lowering blood sugar and controlling body weight, and is a therapeutic drug with great clinical application prospects, which can be used for the prevention and treatment of diabetes , diabetes complications, obesity, or obesity complications. |